JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 21 No. 1 67-70
© 1980 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pastakia, B.
Right arrow Articles by Minkel, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pastakia, B.
Right arrow Articles by Minkel, D.

Tissue Distribution of Copper-Labeled 3-Ethoxy-2-oxobutyraldehyde bis (Thiosemicarbazone) (Cu-64 KTS) in Mice and Rats: Concise Communication

B. Pastakia, L. M. Lieberman, S. J. Gatley, David Young, D. H. Petering and Daniel Minkel

University of Wisconsin Hospital, Madison
University of Wisconsin—Milwaukee, Milwaukee, Wisconsin

Correspondence: For reprints contact: L. M. Lieberman, Sect. of Nuclear Medicine, Univ. of Wisconsin Hospitals, Ctr. for Health Sciences, 600 Highland Ave., Madison, WI 53792.

ABSTRACT

The antitumor activity of, 3-ethoxy-2-oxobutyraldehyde bis (thiosemicarbazone) (KTS), is related to the presence of copper(II) ion. We have studied the tissue distribution of Cu-64-labeled KTS in rats and mice carrying transplanted tumors to evaluate whether the uptake of the radioactivity in the tumor is adequate to warrant further investigation of the tracer as a tumor-seeking agent in patients.

Four groups of three or four animals each were studied: (a) mice with fibrosarcoma; (b) mice with mammary adenocarcinoma; (c) rats with fibrosarcoma; and (d) rats with squamous cell carcinoma of the lung. The animals were killed at intervals of 0.25, 1, 4, 24, and 48 hr after i.v. injection of 1.6 x 10–3 M Cu·KTS containing 3 to 18 µCi Cu-64. Blood, tumor, and six to ten additional tissues were counted for radioactivity.

The mouse fibrosarcoma concentrated Cu-64, reaching 15% of the administered dose/g at 48 hr after injection. This suggests that for tumor scanning, the 61.7-hr Cu-67 might be more suitable as a label for KTS than the 12.7-hr Cu-64.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1980 by the Society of Nuclear Medicine.